Eli Lilly Elects New Directors, Adjusts Officer Compensation

Ticker: LLY · Form: 8-K · Filed: 2024-11-19T00:00:00.000Z

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: LLY

TL;DR

LLY board shakeup and pay adjustments announced today.

AI Summary

On November 19, 2024, Eli Lilly and Company (LLY) filed an 8-K detailing the election of new directors and changes in executive compensation. Specifically, the filing announced the election of new directors and adjustments to compensatory arrangements for certain officers, effective November 19, 2024.

Why It Matters

Changes in board composition and executive pay can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational changes.

Key Players & Entities

FAQ

Who were the new directors elected to the Eli Lilly board?

The filing states that new directors were elected, but does not name them in the provided text.

What specific changes were made to executive compensation arrangements?

The filing indicates adjustments to compensatory arrangements for certain officers, but the specific details of these adjustments are not provided in the excerpt.

What is the effective date of these changes?

The changes related to director elections and officer compensation are effective as of November 19, 2024.

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily to report the departure of directors or certain officers, the election of directors, and changes to the compensatory arrangements of certain officers.

What is Eli Lilly's Standard Industrial Classification (SIC) code?

Eli Lilly's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0000059478-24-000258.txt : 20241119 0000059478-24-000258.hdr.sgml : 20241119 20241119164917 ACCESSION NUMBER: 0000059478-24-000258 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241119 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241119 DATE AS OF CHANGE: 20241119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 241476946 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 8-K 1 lly-20241119.htm 8-K lly-20241119 0000059478 false 0000059478 2024-11-19 2024-11-19 0000059478 us-gaap:CommonClassAMember 2024-11-19 2024-11-19 0000059478 lly:A718NotesDueJune12025Member 2024-11-19 2024-11-19 0000059478 lly:A1.625NotesDueJune22026Member 2024-11-19 2024-11-19 0000059478 lly:A2.125NotesDueJune32030Member 2024-11-19 2024-11-19 0000059478 lly:A625Notesdue2031Member 2024-11-19 2024-11-19 0000059478 lly:A500NotesDue2033Member 2024-11-19 2024-11-19 0000059478 lly:A6.77NotesDueJanuary12036Member 2024-11-19 2024-11-19 0000059478 lly:A1625NotesDue2043Member 2024-11-19 2024-11-19 0000059478 lly:A1.700Notesdue2049Member 2024-11-19 2024-11-19 0000059478 lly:A1125NotesDue2051Member 2024-11-19 2024-11-19 0000059478 lly:A1375NotesDue2061Member 2024-11-19 2024-11-19   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter)   Indiana   001-06351   35-0470950 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)     Lilly Corporate Center Indianapolis, Indiana 46285 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 317 ) 276-2000 Not Applicable (Former Name or Former Address, if Changed Since Last Report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2.): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock (no par value) LLY New York Stock Exchange 7 1/8% Notes due 2025 LLY25 New York Stock Exchange 1.625% Notes due 2026 LLY26 New York Stock Exchange 2.125% Notes due 2030 LLY30 New York Stock Exchange 0.625% Notes due 2031 LLY31 New York Stock Exchange 0.500% Notes due 2033 LLY33 New York Stock Exchange 6.77% Notes due 2036 LLY36 New York Stock Exchange 1.625% Notes due 2043 LLY43 New York Stock Exchange 1.700% Notes due 2049 LLY49A New York Stock Exchange 1.125% Note

View on Read The Filing